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ABSTRACT
Premeditated Enzyme Inactivation:
The Development of Mechanism-Based Irreversible Inhibitors
of Glyoxalase I as Potential Anti-Cancer Agents
Stuart Neal Isaacs
1985
The development of a mechanism-based irreversible inhibitor of an
enzyme is the ultimate proof that a postulated enzymatic mechanism is
operative.

Halogenated methylphenylglyoxals (XV) were synthesized based on

the theory that glyoxalase I proceeds via an enediol intermediate.

The

newly synthesized compounds could divert the enediol intermediate to a
highly reactive species which would then covalently modify the enzyme and
inactivate it-

The in vitro findings of halogen ion release and the

demonstration

of

irreversible

enzyme

inhibition

by

p-

bromomethylphenyiglyoxal provides strong support for the premise that
glyoxalase

I

acts

via

an

enediol

intermediate.

While

p-

fluoromethylphenylglyoxal resulted in no enzyme inhibition, the enzyme
inhibition by p-bromomethylphenylglyoxal might represent the first
mechanism-based inhibitor of glyoxalase I.
Based on the theory that the glyoxalase enzyme system constitutes a
fundamental

regulatory mechanism of

cell

growth and division the

halomethylphenylglyoxals were tested as anti-cancer agents in tissue
culture and in tumor-bearing mice.

Significant cytotoxic effects of

fluoro- and bromomethylphenylglyoxal against L1210 and P388 cell lines were
observed.

In tumor-bearing mice p-bromomethylphenylglyoxal revealed

extreme toxicity, and early death to the mice.

This is consistent with the

potent effect of an irreversible enzyme inhibitor which causes the
overwhelming accumulation of substances which inhibit cell growth and
division.
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INTRODUCTION

It is ...difficult to exaggerate the importance
to biology...of extended studies of enzymes and
their action.
— F.G. Hopkins
(Presidential
address to the Royal Society - 1932)
(1)

The glyoxalase enzyme system
thiohemiacetal (ID of an
corresponding

is now known to convert the

a-ketoaldehyde (D and glutathione (GSH) to the

a-hydroxythioester (III) which is then hydrolyzed by

glyoxalase II to the corresponding D-hydroxyacid Q3Z) and free GSH (Scheme
I).

Since its independent discovery in 1913 by Dakin & Dudley (2,3) and

Scheme I:

0 0
0 OH
OH 0
R-OU-C-CH + GSH ^ RCH9C-C-SG -g-LY- ■*■> RCH9C-C-SG
z 2 i
1 H
n\
1

II

III
GLY II

RCH^-C-O" + GSH
JY

Neuberg (4), the glyoxalase system has been an area of considerable
biological and mechanistic controversy.

Although it has been found widely

distributed (3,5) in animals, plants, and microorganisms, the actual
physiological function of the system remains obscure to this day.

There

are many theories, most with tenuous evidence, of the definitive function
of the glyoxalase system.

3
The theories serve to satisfy the mind, prepare
it for 'an accident' and keep one going. I must
admit that most of the new observations I
made
were based on wrong theories.
My
theories
collapsed, but something was left afterward.
-A. Szent-Gyorgyi (6)
Probably the most controversial theory of the function of the
glyoxalase enzyme system is that proposed by Albert Szent-Gyorgyi, the 1937
Nobel Prize winner in Physiology and Medicine for his work on ascorbic acid
and his studies of cellular respiration.

Szent-Gyo*rgyi has proposed that

methylglyoxal and the glyoxalase system constitute a fundamental regulatory
mechanism of cell division and growth (7-10).

His theory is based on his

observations that a tissue extract, thought to be a ketoaldehyde (9), and
later identified as methylglyoxal (11), reversibly inhibited cell growth
(8).

Szent-Gyorgyi, therefore, designated methylglyoxal as a retarder of

division, the cell's internal "brake".

The glyoxalase enzyme system is

thought to be the promoter of division by the metabolism of methylglyoxal
to D-lactate (10).

A disturbance in this equilibria may be connected with

a cause of cancer.

Szent-GyBrgyi has extended this theory further into an

even more controversial realm of "bioelectronics" (12-19).

In this

submolecular theory, he hypothesized that methylglyoxal is inherently
important in maintaining the energy state of normal living matter, and that
the energy state of living matter is altered in cancer.

His studies using

electron spin resonance have revealed that molecules of major biological
importance, with low chemical reactivity, can give off a whole electron,
thus forming a free radical.

This suggests that charge transfer may be a

common and fundamental biological reaction and he believes that the
presence of methylglyoxal allows such a charge transfer.

He calls

methylglyoxal the "acceptor impurity of protein" whose action is to
desaturate the otherwise electron filled ground state of proteins (15-18).
"If there is a shortage of methylglyoxal or and excess of glyoxalase, there
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is no charge transfer, and cells revert to the simple, non-stoppable
proliferative state, which is cancer." (16)

Therefore, according to

Szent-Gyorgyi's theory, electronic desaturation of protein is a central
event of cell life and a low level of desaturation is seen in cancer
(14,17).
Other researchers have tried to assign different functions to the
glyoxalase system.

Kun (19), who found that methylglyoxal inhibited

succinic dehydrogenase and other similar enzymes suggested that the
glyoxalase enzyme system eliminated spontaneously formed methylglyoxal to
prevent the inactivation of enzymes containing sulfhydry 1-groups.

Salem

(20) supported this idea that spontaneously formed methylglyoxal was
detoxified by glyoxalase and that the wide distribution of the enzyme in
all types of tissues from species of all phyla is in keeping with a role of
this kind.

A Belgium group (21), gave strong evidence that in yeast, the

glyoxalase pathway is a defense mechanism against methylglyoxal produced by
the spontaneous decay of accumulating triose phosphates during glycerol
catabolism.
Recent studies by Gillespie (22-25) suggest that methylglyoxal and the
glyoxalase enzyme system may be involved in the mediation of the immune and
inflamatory responses.

She has shown that the product of the glyoxalase I

reaction, S-lactoylglutathione (III. RrCH-j; Scheme I), is a physiologically
important species regulated by the glyoxalase system.

Concanavalin A is

known to increase centriole-associated microtubules in polymorphonuclear
leukocytes (23).
the

In vitro studies revealed that this assembly occurred in

same time frame of glyoxalase I activation, resulting in the buildup

of S-lactoylglutatione.

This thioester was also shown to be a potentiator

of histamine release in human leukocytes (24).
ester,

Her work with a phorbol

a known inflamatory agent and potent carcinogen,

revealed that it

caused elevated glyoxalase I activity and decreased glyoxalase II activity
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in human leukocytes (25).

This is compatible with the hypothesis that

increased levels of S-lactoylglutathione are a concomitant of inflamation.
It is also possible that the increased levels of this thioester is related
to the tumor promoting properties of phorbol esters.

This is all

consistent with Szent-Gyorgyi's theory that cancer cells have increased
glyoxalase activity which cause a decrease in endogenous methylglyoxal.
Others doubted the existence of intracellular methylglyoxal and
postulated that the glyoxalase system was involved in the reactions of
other intracellular ketoaldehydes.

Thus, some naturally occuring

ketoaldehydes, phosphohydroxypyruvic aldehyde (26), hydroxypyruvic aldehyde
(27), and y,S-dioxovalerate (28), were shown to be substrates of the
glyoxalase enzyme system.
The debate over the existence of methylglyoxal as a natural
constituent of cells was finally concluded in 1970 when Cooper and co¬
workers (29-31) made the important discovery of the enzyme methylglyoxal
synthase.

This enzyme originally found in £*. coli.

catalyzes the

conversion of dihydroxyacetonephosphate (DHAP) to methylglyoxal and
phosphate.

Previous to this discovery, some thought that the methylglyoxal

found in cells was formed non-enzymatically (32,33).

Methylglyoxal

synthase serves as a bypass of triose-phosphate isomerase.

Methylglyoxal

synthase, in conjunction with glyoxalase and D-lactate dehydrogenase,
constitutes an alternative to the Embden-Meyerhof glycolysis pathway (29).
(See Scheme II).

This bypass does not result in ATP formation because it

bypasses both substrate-linked phosphorylations of glycolysis.

At first.

Cooper (29) thought that it might play a role by preventing the
accumulation of high concentrations of phosphorylated glycolytic
intermediates which inhibit growth.

Later, his data (30,31) suggested that

the pathway would be important when glycolysis was restricted by reduced
availability of inorganic phosphate (P^).

With decreased P^,
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Scheme II:(29)
glucose

l

glucose-6-phosphate

jr

fructose-6^phosphate
FRUCTOSE-1y6-DIPHOSPHATE
DI HYDROXY ACETONE-PHOSPHATE ?=iGLYCERALDEHYDE-3-PHOSPHATE

>I
1,3-DIPHOSPHOGLYCERATE
METHYLGLYOXAL

D-LACTATE

J[

3-PHOSPHOGLYCERATE

Jf
Jf
PHOSPHOENOLPYRUVATE

2-PHOSPHOGLYCERATE

^

)

PYRUVATE-x

glyceraldehyde-3-phosphate dehydrogenase would be inhibited and as a
consequence the triose phosphate concentration would rise.

The bypass

scheme would then function by methylglyoxal synthase liberating P^, thus
replenishing intracellular P^, and then glyoxalase would generate lactate
which is an energy source under aerobic conditions.

Methylglyoxal synthase

was initially found in bacteria and has more recently been found in rat
liver (34) and isolated from goat liver (35).

Thus, the existence of an

enzyme to make methylglyoxal suggests that this compound may indeed have a
significant biological role.
Even though Szent-Gyorgyi's theory that the glyoxalase system
constitutes a fundamental regulatory mechanism for cell division and cell
growth remains controversial, it has, none-the-less, stimulated much
thought and research on the possible connections of this enzyme system and
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cancer.

Work which lends some support to Szent-Gyorgyi's theory are the

studies of glyoxalase activity in cancerous tissues and tissues undergoing
rapid growth; as well as studies of the keto-aldehyde's inhibitory effects
on cell growth and division.

Early studies (36) generally showed no

evident differences between cancerous and normal animals in the glyoxalase
content of corresponding organs.

More recent studies by Norton and co¬

workers (37) have shown that for the first ten days after tumor implant,
there is an increase in tissue glyoxalase enzyme activity versus tissues of
normal animals.

The increased glyoxalase activity during the early stages

of tumor formation goes along with Szent-Gyorgyi's theory that glyoxalase,
by metabolizing methylglyoxal, is a cell growth promoter.

However, after

ten days there is an overall decrease in glyoxalase activity in tumor¬
bearing mice, but this decreased activity paralleled the decreased activity
seen in other enzymes studied in tumor bearing mice.

Norton's group also

showed that the glyoxalase I enzymes isolated from the liver of tumor¬
bearing mice and normal mice were different protein molecules, but, with
the same pH optima and Km's.

They concluded that the glyoxalase I isolated

from tumor-bearing mice was modified due to the presence of tumor (38).
Brandt (39) studied the possible changes in the glyoxalase system with
rapid growth.

He found that the final product of the glyoxalase reaction,

D-lactate, was increased in the blood of rats at the end of their rapid
growth phase.

He concluded that if D-lactate concentration reflects

cellular methylglyoxal levels, then the hypothesis that methylglyoxal is a
natural growth inhibitor is supported because, as observed, its level would
increase as the animals reach the end of their rapid growth phase.

An

Italian group (40) studied glyoxalase I and II activity in the regenerating
rat liver.
rapidly.

Rat liver regeneration peaks at 28 hours and then falls

They found significantly increased glyoxalase I activity at 24 to

48 hours after partial hepatectomy.

The high glyoxalase I activity during
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the regeneration period support Szent-Gyorgyi's theory that glyoxalase I
activity reduces the intracellular content of growth inhibitors.

Increased

glyoxalase II activity at 16, 48, and 72 hours with a transient decrease in
activity at 24 hours, was correlated with an interval when proliferative
activity is nearly stopped.

Therefore, they proposed that it was the

changes in concentration of the thioester, the intermediate compound
between the glyoxalase I and glyoxalase II reaction, that is also important
in growth regulation.

That is, a decrease in this substance, by increased

glyoxalase II activity, causes cellular proliferation to be shut down.

In

support of this, a Polish group (41) found that glyoxalase II activity was
absent in cancerous tissues and cells.

They claimed that this is a

characteristic feature that distinguishes cancerous tissues from normal
tissues.

Thus, they agree with Szent-Gydrgyi that a fundamental factor in

the cancer process is a disruption in the glyoxalase enzyme system.
The effects of ketoaldehydes on growth and division have been known
for a long time.

They have been tested as viricidal agents (42-46), and

are known inhibitors of bacterial and cellular growth and division (8,47—
50).

Egyiid & Szent-Gydrgyi (8) found that low levels of methylglyoxal

inhibited cell division of

coli.

flagellates and cells in tissue culture.

fertilized sea

urchin eggs,

Methylglyoxal has also been found

to inhibit adult kidney cell growth (50).

Ketoaldehydes have also been

extensively studied as possible carcinostatic agents (51-55), and, in fact,
the ketoaldehyde, 3-ethoxy-2-ketobutyraldehyde (Kethoxal
marketed as a carcinostatic drug.

) was at one time

In experimental set-ups, the glyoxal

compounds have been found to be most active against mice ascites carcinoma,
mammary carcinoma, leukemia, adenocarcinoma,
(53,54).

lymphosarcoma, and sarcoma

Egyiid & Szent-Gydrgyi (54) noted that cancer cells in tissue

culture were more sensitive to the inhibitory effects of methylglyoxal than
normal cells in culture.

However, the chemotherapeutic value of

»-
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ketoaldehydes are limited by their rapid metabolism by the

glyoxalase

system.
The observations of the potent inhibitory effects of the ketoaldehydes
led to the studies of how this inhibition occurred.

Early on, Egyiid &

Szent-Gyorgyi (8) showed that the inhibition was not due to the cessation
of oxidative metabolism.

Their biological studies on E. coli (56) using

radioactive compounds revealed that methylglyoxal inhibited protein
synthesis and to a lesser degree, DNA and RNA synthesis.

This has been

confirmed (57,58) and similar results have been obtained using malignant
ascites cells (59), mouse lymphoma cells (49), and cultured guinea pig
keratocytes (GFK) (60).

The effect of the inhibition is to stop cells from

continuing through their life cycle, regardless of where the cell is in the
cell cycle when the ketoaldehyde is added.

One study on

coli (58)

showed that methylglyoxal, by interfering with protein synthesis, inhibited
DNA synthesis by interacting with an initiation complex.

They also found

that methylglyoxal disrupted cell division by preventing the synthesis of a
termination protein required for cell division.

Another study on GPK cells

(60) showed that methylglyoxal directly inhibited protein and RNA synthesis
individually.

The inhibition of protein synthesis resulted from an

inhibition of the initiation of translation.

RNA synthesis was inhibited

by a block in the maturation of the 32S rRNA precursor.

Methylglyoxal has

also been shown to react with the 7-methylguanosine cap structure of
eukaryotic mRNA to cause an inhibition of protein synthesis

(61).

Recently, Riley (62) determined that a methylglyoxal-ascorbate adduct (NFCR
278021) isolated by Fodar, effectively inhibited protein synthesis.

The

inhibitory effect of the adduct on protein synthesis was found to be
decreased in the presence of GSH and glyoxalase.
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To [attempt] cure.. .without understanding it is
similar to trying to repair a machine
without
knowing hew it works.
-A. Szent-Gyorgyi (63)
Throughout the years of controversy of the biological role of the
glyoxalase enzyme system, a detailed understanding of the catalytic
mechanism was accumulated.

The first theory of the mechanism by which

glyoxalase functions was put forward by Dakin & Dudley (3) who observed
that the reaction was similar to the in vitro reaction of ketoaldehydes in
alkaline solution (i.e. what is now called a Cannizarro Reaction).
(64)

discovered that the tripeptide,

Lohmann

-glutamylcysteineglycine or

"glutathione" (GSH) was a coenzyme of glyoxalase.

Jowett & Quastel (65)

proposed the formation of a condensation product between methylglyoxal and
glutathione (GSH) as an intermediate to lactic acid production.

Yamazoye

(66) was first to show the presence of an intermediate distinct from the
addition complex between methylglyoxal and GSH in crude tissue extracts. It
was not until 1950 when Hopkins & Morgan's (67) "factor" which accelerated
the glyoxalase reaction was identified by Racker (68,69) and Crook & Law
(70,71) as another enzyme which was present in the original crude
glyoxalase preparations.

Thus, two individual enzymes, glyoxalase I and

II, were firmly identified.

Of equal importance, Racker introduced a

spectophotometric method of following the glyoxalase reactions, thus
replacing the cumbersome manometric techniqes used in the past.

Both

groups also determined a difference between the chemical condensation
product and Yamazoye's biological product.

The chemical intermediate

(proposed as XL, Scheme III) was unstable in acid and alkali, decomposing
to methylglyoxal and GSH.

The biological product (proposed as Ilia. Scheme

III) formed by the action of glyoxalase I was stable on the acid side of
neutrality and decomposed to lactic acid and GSH on the alkaline side of
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neutrality.

Both groups proposed reaction pathways similar to Scheme III.

Scheme III:(adapted fran 70)
0 OH
RCI^C-C-SG (labile)
II
(stable
canpound)
■

0 0

0 0

rch2c-ch

RCH2C-CH + GSH

. GSH
Ilia

I

'

OH 0
GLY -U> RCHoC—C-0~ + GSH

^H
IV

At that time. Crook & Law (71) also noted the low specificity of the
enzymes for the glyoxal substrate but the very high specificity of
glyoxalase for the GSH coenzyme.

In 1961, Cliffe & Waley (72) gave

evidence that the thiohemiacetal adduct II was the substrate for glyoxalase
I.

This was shown in a reaction at high glyoxalase I concentration and low

methylglyoxal and GSH levels.

The rate of the reaction was revealed to be

determined by the non-enzymatic formation of the thiohemiacetal (II).

This

was confirmed by Davis & Williams (73) who concluded that glyoxalase I acts
as an oxidoreductive isomerase.

Thus, Scheme I is the accepted pathway of

the glyoxalase enzyme system.

Further confirmation of a one substrate

pathway have been offered by Vander Jagt (74) and Marmstal & Mannervik
(75).

It is known that the product of glyoxalase I reaction is

stereospecific and an initial study (76) using high-resolution 1H-NMR
revealed that glyoxalase I selected the proper thiohemiacetal diastereomer
for processing.

The investigators concluded that the most likely origin of

the product stereochemistry was a selective binding site on glyoxalase I
for the proper diastereomer.

However, this was not confirmed by Creighton
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(77) who found through a series of isotope-trapping experiments that
glyoxalase I operated on the mixture of thiohemiacetal diastereomers.
Chari & Kozarich (78) have recently deduced the absolute stereochemical
course of glyoxalase I.

Their work supported the finding of a single

stereochemical outcome of the two thiohemiacetal isomers when processed by
glyoxalase I.

However, this most likely occurred by an epimerization of

the wrong isomer prior to the stereospecific proton abstraction by
glyoxalase I which results in a single stereospecific product.
As stated previously (71,74,79), glyoxalase I was found to have a
broad specificity for both aliphatic and aromatic
(reflected by nearly identical Vmax).
if the side chain of the
in nature.
constraint.

a-ketoaldehydes

However, the Vmax dropped abruptly

a -ketoaldehyde was sterically crowded or polar

Thus, the active site has a non-polar region and has a space
Mannervik (80,81) has shown that sulfhydryl groups on the

enzyme are not involved in glyoxalase's catalytic activity and that a
tryptophan near the active site is involved in the binding of the
substrate.

Reed (82) using a similar experimental technique found an

arginine residue near the active site that is involved in substrate binding
via the GSH.
A metal ion at the active site was suggested by Davis & Williams (83)
when they found that during purification a metal-chelator totally
inactivated the enzyme.
Mg++ ions were added.

The activity was restored most effectively when
They theorized that the divalent cation played a

direct part in the catalysis of the thioester formation.
and co-workers (84) found that it was actually Zn
to glyoxalase I.

Later, Mannervik

that was tightly bound

They felt that the metal ion acted in the catalytic

reaction or that it functioned to maintain the enzyme structure.

Later

work (85,86) by this group proved that the zinc ion was at the active site
of the glyoxalase I enzyme.
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The mechanism of glyoxalase I has been an area of as much controversy
as that centered on the biological role of the glyoxalase enzyme system.
Racker (69) proposed that the mechanism of glyoxalase I was through an
enediol intermediate (Va. See Scheme IVa) which would proceed via a proton
Scheme IV:

(0 OH
RCH2-C^C-SG
H

' W "
RCH2C=tC-SG

Hb-Enz

*-;B-ENZ

©
Va

0 0

IW

OH 0
RCHoC—C-SG
ZH
III

W
RCHo-C-C-SG

GLY I

2*®
II
transfer.

However,

when Rose (87) ran the glyoxalase I reaction in

tritiated water, he failed to observe the incorporation of tritium into the
product and this contradicted the possibility of an enediol intermediate.
Because the conversion of methylglyoxal to lactic acid resembled the
Cannizzaro reaction, (an alkaline catalyzed reaction known to convert
methylglyoxal to lactic acid by a direct 1,2-hydride shift) he proposed
that the glyoxalase I reaction was analogous to the Cannizzaro reaction and
therefore the mechanism was a direct 1,2-hydride shift (See Scheme IVb).
These results were confirmed when Franzen (88) failed to detect the
incorporation of

deuterium in the product of the glyoxalase I reaction

run in deuterated solvent.
Davis & Williams (83) supported a hydride shift mechanism which would
proceed via a cyclic transition state of the thiohemiacetal (IX) and the
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newly discovered metal cation.

Such a mechanism was a variation of the

Meerwein-Ponndorf-Oppenauer reaction.

Vander Jagt (79,89,90) favored the

1,2-hydride shift mechanism of glyoxalase I, however, some of his results
made him question this conclusion.
specificity of glyoxalase I for

For instance, in his work on the broad

a-ketoaldehydes,

he found no substituent

effect of the substituted a -ketoaldehydes on the rate of the reaction
(79).

If the mechanism was a hydride shift, one would expect to see a

substituent effect depending on the polarity of the

a-ketone carbonyl

(due to the transition state stabilization by electron withdrawing groups).
This substituent effect existed in the alkaline catalyzed Cannizzaro
reaction (89).

He felt that the above observations suggested that either

the hydride shift was not the rate determining step or that the hydride
migration was facilitated through the polarization of the <* -ketone group
ty the enzyme.

In the latter case the effects of substituents may be small

and the hydride shift could still be rate determining (79). However,
experiments (90) measuring deuterium isotope effects revealed that the
hydride shift was rate determining, and he therefore concluded that the
side chains of substituted

a -ketoaldehydes do not make a significant

contribution to the polarity of the a -ketone group because the enzyme
polarizes the a-ketone group in some way.
Hall (91) studied the rearrangement of a -ketoaldehydes (D and thiols
to

a -hydroxyesters (ill) in the presence of a "general base" (e.g. a

tertiary amine) and deuterated solvent and found deuterium incorporation in
the

-hydroxyester.

But it was not until 1976 when Hall, et al. (92)

detected the incorporation of solvent protons into the product of the
glyoxalase I reaction.
temperature.

The percentage of incorporation increased with

His group proposed a mechanism whereby a fast proton transfer

via an enediol was taking place in a highly protected active site.
Experiments measuring deuterium isotope effects (93) indicated that the

15
hydrogen transfer was rate limiting, but did not distinguish the nature of
the hydrogen transfer.

Another group (94) provided further evidence for a

proton transfer mechanism when they detected the slow exchange of the
hydroxymethylene proton of the product, S-CD-lactqyl)glutathione (III) with
solvent.
A problem with solvent incorporation as a means of determining the
reaction mechanism is the possibility of proton exchange occurring by a
fortuitous side reaction after the catalytic step and prior to product
release.

This had led researchers to continue to investigate the reaction

mechanism of glyoxalase I.

Shinkai

(95)

using a "flavin-trapping"

technique provided evidence that the chemical reaction occurred via an
enediol intermediate.

Complete reaction inhibition was seen in a test

model system of the general base catalyzed rearrangement of thiohemiacetals
to the corresponding

a-ketoacids in the presence of a flavin compound.

Flavin compounds react with transient carbanion intermediates, but do not
serve as efficient hydride acceptors.
Recently, Kozarich (96-98) designed experiments which definitively
proved the glyoxalase I mechanism to be that of a proton transfer.
design

(98)

centered around the expected differences in the charge

densities on the C-2 position of the ketoaldehyde.
mechanism

The

In the enediol

(Scheme iva) one would expect the buildup of carbanionic

character at this carbon in order to enhance proton transfer from the
active site base.

In the hydride shift pathway (Scheme IVb) one would

expect an increase in carbonium ion character at this carbon in order to
facilitate the transfer of the hydride from the C-l position of the
thiohemiacetal.

With the proper substrate, one could distinguish between

the two mechanisms.

The group synthesized halomethylglyoxals Qa) which

would be sensitive to the charge density on the C-2 carbon.

Thus, if the

enediol mechanism was correct one would expect the possibility of halide
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elimination (Scheme V).

Scheme V:

(adapted from 96)

0 0

II

However, one would expect no halide elimination if

II

CP pH

X-CH2-C-CH + GSH 5=^ X-CH2-C^C-SG
H
■:B-ENZ

X: F, Cl, Br

vi

XjCH2^C-SG

viii

VII

+ X'

x-ch9-c-c-sg
z H
Xa

0 0
Ti it

H3C-C-C-SG

GLY II

Xb

GLY II

0n 0n

OH (3

'

GSH + X-CH9-C-C-0"
z H

H3C-C-C-O" + GSH

HALOLACTATE

the hydride transfer mechanism was operating.

PYRUVATE

And, in fact, under typical

Cannizzaro reaction conditions, no halogen was released.

The above

experimental design eliminated the possible ambiquity of solvent
incorporation.
Fluoromethylglyoxal (VI? X=F) was studied (96) and the results were
consistent with a rapid proton-transfer mechanism.

As hypothesized, the

enzymatic reaction with glyoxalase I yielded total fluoride release which
could best be accounted for by a carbanionic character at

C-2.

If the

17
same reaction was performed in the presence of both glyoxalase I and II,
then three products were obtained (See Scheme V).

F-NMR determined that

the only fluorine containing products were fluorolactate and fluoride.

The

other product was pyruvate (determined to be present enzymatically).

The

above results could best be accounted for by Scheme V, which shows the
unique glyoxalase I catalyzed partitioning of the enediol intermediate
between protonation to yield S-fluorolactqylglutathione CXa, path a) and
elimination of fluoride to first form an enol (IXb. path b) which then
tautomerizes to form S-pyruvylglutathione (Xb. path b).

Hydrolysis of the

thioesters by glyoxalase II yields the products fluorolactate (path a) and
pyruvate (path b) which undergo no further reactions.

This example of

product partitioning provided strong support for the proton transfer
mechanism.
However, the results outlined above could also be accounted for by a
fortuitous side reaction by an active site base after the catalytic step.
Thus, the possibility of a 1,2-hydride shift was not ruled out.

The

definitive proof of the enediol intermediate of the glyoxalase I reaction
was

shown

by

isotope

effects on the product

fluoromethylglyoxal-d^, (97).

partitioning

of

Isotope effects in the past (90,93) were

unable to distinguish between the two possible mechanisms.

The difference

in Kozarich's design was that an isotope effect on the unique partitioning
of products of the glyoxalase system reaction would allow one to
distinguish between proton transfer and hydride shift with 6-elimination.
Since the observed partitioning measures the competition of two kinetic
processes (i.e. fluoride elimination versus protonation) the selective
disruption of one of these rates would have resulted in a change in the
observed partitioning.

If the enediol mechanism was correct (Scheme VI),

abstraction of the deuterium from C-l by the active base would result in
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Scheme VI:<97)

F-C^-C-C-SG
D

'0 OH

F-CHj-C^-SG
D:" r“'’

OH 0
I

II

h2c=c-c-sg +
the formation of the enediol and deuterated base.

r
Now a primary isotope

effect on the reprotonation of the enediol at C-2 would result in a delay
in the formation of fluorolactoylglutathione and the overall effect would
have been to increase fluoride elimination (kD is selectively decreased by
the isotope effect on the dueterated base, Scheme VI).

The opposite result

was expected if the hydride shift mechanism was operative.
shift

from

the

thiohemiacetal

would

have yielded

fluorolactoylglutathione directly (Scheme VII).

OH 0
"

?H(?

F-CH,-C—C-SG
Z I

D
:B-ENZ

on o
H2C=C-C-SG + F"
D:B-ENZ

deuterated

The primary isotope effect

Scheme VII:(97)

I

A 1,2-deuteride
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would result in a decrease in the rate of elimination and the overall
effect would have been to decrease fluoride elimination (kg^ is selectively
decreased by the isotope effect on deuterated C-2, Scheme VII). Chari &
Kozarich's results (97) clearly demonstrated an increase in the amount of
fluoride released when the deuterated substrate was compared to the nondeuterated compound.

This finding was only consistent with a primary

isotope effect on the partitioning reaction involving a proton transfer to
an enediol intermediate.

Thus, this established a compelling argument for

the proton transfer mechanism of glyoxalase I first proposed over thirty
years ago (69).
During Kozarich & Chari’s studies with halomethylglyoxals, they
discovered a unique example of "inverse" substrate processing by glyoxalase
I.

This work (99) has re-emphasized the need for glutathione for substrate

binding, as well as the requirement of thiohemiacetal formation for
catalysis.

It also gives further information about the "size" of the

enzymatic active site, which in the past (74) was found to have a poor fit
with sterically hindered side chains of substituted a-ketoaldehydes.
Scheme VIII depicts the method by which
form

Kozarich & Chari

were

able to

B-(alkylthio)-a -ketoaldehydes Oil) and specifically the glutathione

adduct (XI. R=GSH).

When B- (glutathiomethyl) glyoxal was processed through

Scheme VIII, pathway a, the majority of product formed was L-lactate.
Ifaus, one observed a total reversal of the expected stereochemistry of the
glyoxalase enzyme.

The investigators, therefore, proposed that the

substrate binds to the active site in an inverted manner allowing the
stereochemistry to be reversed.

They termed this process "mirror-image"

catalysis and proposed Figure 1 as a possible explanation.

Figure 1A

depicts normal binding in which glyoxalase processing would form the Disomer.

Figure 2B illustrates the inverted binding of the "inverse"
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Scheme VIII:

(adapted fran 99)
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Figure 1:(99)

substrate which due to the constraints of the system necessitates the
opposite processing resulting in the L-isomer.
Glyoxalase I [S-lactoylglutathione methylglyoxal-lyase (isomerizing)
EC 4.4.1.5] has been isolated in high purity from a number of different
sources ranging from yeast (90), mouse liver (38,100,101), sheep liver
(102), and various tissues from rat (103).

The molecular weight of the

mammalian enzyme has been found to be between 45,000-52,000.

In contrast

to the yeast enzyme, Oray & Norton (100) were the first to discover that
mammalian glyoxalase I consisted of two identical subunits.
that each subunit has an active site (80,81).

It appears

Vander Jagt (103) showed

that within a species there is only a single form of the enzyme.

However,

between species, the activities, properties and amino acid composition of
glyoxalase I vary (104).

This has been supported by Chari & Kozarich (97)

who found different partitioning ratios of products depending on the origin
of enzyme used.
Glyoxalase II [S-2-Hydroxyacylglutathione hydrolase, EC 3J.2.6) which
catalyzes

the

hydrolysis

of

the

thioester

a-hydroxyacid has also been highly purified.

to

the

corresponding

Like glyoxalase I it is

highly specific for GSH, but unspecific for the acylgroup of the thioester
(105).

Its molecular weight is about 30,000 (106) and its activity is

normally less than than of glyoxalase I (107).
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...I believe...[methylglyoxal] is the universal
brake of proliferation...and glyoxalase is its
switch.
-A. Szent-Gyorgyi (14)
Because one of the major roles suggested for the glyoxalase enzyme
system is that of regulation of cell growth and division, the possibility
exists that cancer cells have lost their ability to maintain a proper
balance of methylglyoxal.

Attempts have been made to try and influence the

complex equilibria between methylglyoxal, glyoxalase, and lactic acid.
a-Ketoaldehydes are known growth inhibitors.

The problems of achieving

suitable doses of methylglyoxal or other reactive ketoaldehydes for
systemic control of cell growth and division are due to their inherent
toxicities, as well as the widely distributed glyoxalase system which
causes their inactivation.

Another approach to disturb the regulatory

system has been the development of inhibitors of glyoxalase I, the enzyme
which converts

a -ketoaldehydes and glutathione to thiohemiacetals.

In

the past, this enzyme has been shown to have increased activity in
cancerous and regenerating tissues.

Therefore, by inhibiting this enzyme

one could possibly disrupt growth by allowing the intracellular buildup of
growth inhibiting substances.

Another goal in the development of enzyme

inhibitors is their usefulness as probes in elucidating the mechanism and
possible biological significance of an enzyme system.
Research first centered around the design of competitive inhibitors of
glyoxalase I.

Kermack & Matheson (108) found that various analogues of

GSH, the most active having a large alkyl group substitution, to be pure
competitive inhibitors of glyoxalase I.
by

Vince

and

co-workers

bromobenzylglutathione,

Similar inhibitors were developed

(109,110)

whose

compound,

S-p-

is presently the best reversible inhibitor known,

with 50% enzyme inhibition

of 0.009 mM.

They found these compounds to

be cytotoxic versus L1210 leukemia and KB cells in tissue culture.

Vince
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(110) stated that by increasing the intracellular methylglyoxal, one
inhibited protein synthesis.

Protein inhibition occurred by methylglyoxal

binding to RNA guanine residues.

This adduct was stable at acid pH (111)

and therefore Vince hypothesized that one might be able to have selectivity
in methylglyoxal's effect on cancer versus normal tissue.

Norton (112),

using the fact that S-substituted glutathiones strongly interacted with
glyoxalase I,

developed S-substituted glutathiones for the use as ligands

for the affinity chromatography purification of glyoxalase I.
Vince (113,114), noted that the S-substituted competitive inhibitors
were rapidly metabolized In vivo by glutathionase, rendering the inhibitors
inactive.

He then developed glyoxalase I inhibitors which could resist

degradation.

However, these S- and N- substituted cysteinylglycines

exhibited non-competitive inhibition of glyoxalase I and Vince therefore
concluded that they were binding to a site other than the active site.
Recently (115) esters of several glutathione analogues were synthesized in
which the glycine was replaced by a straight-chain fatty acid and the
mercapto group was benzylated.

This type of compound, which inhibited

glyoxalase I, was not hydrolyzed by glutathionase or cysteinylglycinase and
has high lipohilicity.

However, they did not inhibit P388 lymphocytic

leukemia in mice.
Hall (116) synthesized

a-hydroxythiol esters and found them to be

competitive inhibitors of glyoxalase I.

However, when tested against L1210

leukemia cells, he found no antitumor activity and thought this might be
due to the ease of hydrolysis of the compound In vivo.
Oray & Norton (117) found that both glyoxalase I and II from different
tissues were equally inhibited by nucleotides and nucleosides in an
apparently cooperative manner.

They raised the point that intracellular

levels of the tested nucleotides are at concentrations higher than what was
needed to inhibit both enzymes.

The physiological significance of this has
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not been shown.

Another interesting competitive inhibitor of glyoxalase I

was studied by Douglas (118).

He showed that yeast glyoxalase I was

inhibited by porphyrin derivatives, possibly by active site occlusion.
referred to earlier (28),

As

y , 6 -dioxovalerate, the transamination product

of the first committed intermediate of porphyrin biosynthesis, is a known
substrate of glyoxalase I.

This possible complex interrelationship of

glyoxalase with the heme biosynthetic pathway has not been worked out.
From the above data, it appears that some competitive inhibitors are
excellent glyoxalase I inhibitors in vitro.

However, mostly because of

their own metabolism and inactivation, competitive inhibitors are not
likely to be useful inhibitors of glyoxalase I in vivo.

Therefore,

attention turned to the development of mechanism-based, transition-state
(119) inhibitors where tighter binding of the transition state analog
occurs.

The mechanism of glyoxalase I is known to proceed through an

enediol intermediate.

Therefore,

Douglas & Nadvi (120) synthesized

compounds designed on transition state analogy.

The compounds all

resembled the enediol intermediate, (See Figure 2) and showed excellent

Figure 2:(U9)

if

HO

H0'\}

a.

b.

inhibition, but had inhibition constants no better than the competitive
inhibitor p-bromobenzylglutathione and are therefore excluded as tansition
state analogs.

Similarly, Brandt, et al. (121) selected compounds to test

on their similarity to the enediol intermediate of the glyoxalase I
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reaction.

They found that some derivatives of couraarin (See Figure 2d) to

be the most effective inhibitors of this type with a

of 0.03 mM.

But

this still is not as good as inhibition by p-bromobenzylglutathione.
Therefore, no effective transition state based inhibitor has been found for
glyoxalase I.

Suicide inactivators...depend upon the specific
catalytic capabilities of the active site.
-Abeles & Maycock (122)
The main goal of my project was to synthesize a potential mechanismbased, suicide inhibitor of glyoxalase I.
were aware of the possibility that their

Kozarich and

co-workers (96)

halomethylglyoxals could function

as mechanism-based inhibitors of glyoxalase I.

They proposed a mechanism

(see Scheme IX) whereby the transient enol (ixb) of S-pyruvylglutathione
Scheme

VI

IX:

VII

VIII

i

n

ch2^:-c-sg + x“
ENZ-Nuc

IXb

oh 9
Enz-Nuc-CH9-C—C-SG
z H
XIV
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generated by halide elimination, might be susceptible to Michael addition
by an active site nucleophile.

This would result in covalent modification

and inactivation of the enzyme (XIV).

Kuo, et al. (123) have shown that

the enol of pyruvate is sufficiently long lived for Kozarich's proposed
Michael addition to occur.

However, no inactivation was detected (96).

Trapping experiments (98) suggested the presence of (IXb) in solution.
Therefore, inactivation might not have been seen because an active site
base was not accessible to the enol (IXb) for attack, or that IXb was not
sufficiently active to undergo Michael addition.

In order to take

advantage of the enediol intermediate, p-halomethylphenylglyoxals were
synthesized.

These compounds could divert the enediol to a highly reactive

species which could covalently modify glyoxalase I and inactivate it (See
Scheme X).

When the thiohemiacetal of XV and GSH react with glyoxalase I,

the corresponding enediol (xvil) is generated.

The intermediate could

follow path a. Scheme X, and undergo fast-shielded protonation to yield the
thioester (XVIII).

Or the enediol could follow path b. Scheme X, and

eliminate the halogen to generate the very reactive quinoid-like structure
XIX which is an electron deficient species,

xix would then be highly

susceptible to Michael addition by an active nucleophile which could attack
it and

form a

covalently modified enzyme,

XX.

Thus,

the

halomethylphenylglyoxals are potential mechanism-based inhibitors of the
glyoxalase enzyme system and therefore might ultimately prove to be useful
antineoplastic agents, as well as be useful in further elucidating the
physiological role of the glyoxalase enzyme system.
The compounds I prepared, p-bromohad previously never been synthesized.

and p-fluoromethylphenylglyoxal

They were studied with glyoxalase I

In vitro using standard enzymatic techniques.

Some of the products of the

enzymatic reactions were identified by NMR analysis.

The reaction

mechanism of an intermediate enediol was studied by employing techniques of
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Scheme X:
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specific ion electrode analysis.

Inhibition of glyoxalase I was

investigated using standard techniques of kinetic analysis.

The compounds

were also tested in cell culture against L1210 and P388 cell lines as an
initial screen for antitumor activity.

Finally, the halogenated

methylphenylglyoxal's anti-cancer activity were tested in vivo in tumor¬
bearing mice.
The newly synthesized halomethylphenylglyoxals were also used to form
p-glutathiomethylphenylglyoxal (XXIV) which was then studied as both a
substrate and

a potential inverse substrate of glyoxalase I.
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MATERIALS AND METHODS

A.

SYNTHETIC METHODS

Starting materials were of analytical grade from either Aldrich or
Fisher Scientific, unless otherwise noted.
stored over molecular sieves.

Solvents were distilled and

Melting points were determined on a Thomas-

Hoover capillary melting point apparatus and are uncorrected.

^H-NMR

spectra were routinely recorded in the noted solvent on a Varian T-60A
Analytical NMR Spectrometer.

The chemical shifts are expressed in 6 values

(parts per million) relative to Me4Si internal standard.
were performed by Atlantic Microlab, Inc., Atlanta.

Microanalyses

Analyses are indicated

by symbols of the elements and represent analytical values which were
within ± OJ. % of theoretical values.

Ultraviolet spectra were determined

in a potassium phosphate buffer with a Beckman Model 35 Spectrophotometer.
Mass spectra data was obtained on a Hewlett-Packard 5985 GC Mass
Spectrometer.

Purification O-f N-bromosuccinimide (NBS) — Following a literature
procedure (124), NBS (25g) was added to boiling distilled water (250 ml)
and swirled for about two minutes until all the crystals were dissolved.
The resulting yellow solution was poured through a fluted filter into a
flask immersed in an ice-water bath and allowed to stand in the ice bath
for two hours.

The resulting mixture was then filtered through a Buchner

funnel with suction.

The white crystals were washed with two portions of

ice-cold water (50ml) and then dried first under water vacuum and then in a
lyophilyzer for 24 hrs.

Yield:

58%.

Synthesis oL p-bromomethvlacetophenone — Following a previously reported
procedure (125), NBS (14.0 grams; 0.079 moles), benzoylperoxide (10 mg).
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and p-methylacetophenone (10.6 g;
tetrachloride (90 ml).

0.079 moles) were mixed in carbon

This solution was held at reflux and irradiated

with a 275-W sun lamp for about one hour (until the originally floating NBS
appeared to be converted entirely to succinimide which sinks in CC14).

The

solution was filtered and the solvent removed by rotary evaporator.

The

liquid was distilled under

reduced pressure to yield 10.6g of p-

bromomethylacetophenone (63% yield), bp 99-100° (0.05 mmHg), NMR (CDCI3):
<5 =7.2-7.8 (q,4H), 4.4 (s,2H), 2.2 (s,3H).

p-Bromomethylphenylalyoxal [The proper name is 4-bromomethyl-a-oxobenzeneacetaldehyde,

— This compound was synthesized by oxidation of

p-bromomethylacetophenone with selenous acid following a modified
literature procedure (126).

A solution of selenous acid (2.24 g; 0.017

moles) and dioxane (15 ml) was heated at "55 °C for 15 minutes until all the
solid had gone into solution.

p-Bromomethylacetophenone (3.89 g? 0.018

moles) was added in one lot and the reaction mixture, under a constant
stream of argon gas, was slowly brought to reflux and held at 98-100°C for
2 hours.

The warm solution was decanted off the precipitated black

selenium metal and concentrated on a rotary evaporator.

Column

chromatography was performed to isolate the desired reaction product.

A

glass column (inner diameter = 3.5 cm; length = 80 cm) was filled with
silica gel (175 g).

A total of ~2 liters of solvent starting with 20%

ethylacetate in hexanes and ending with 100% ethylacetate was used for
product elution.

A Buchler Automatic Fraction collector was used to

collect "20 ml fractions.

The isolated products within each fraction were

identified by thin layer chromatography (TLC eluting solution:
hexanes,

50%

ethylacetate).

The

desired

product,

50%
p-

bromomethylphenylglyoxal eluting at 20% hexanes and 80% ethylacetate
solution, was concentrated under reduced pressure and determined to be >95%
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pure by nmr. (Column yield: 37%) mp. 101~103°C; NMR (acetone-dg):
(s,0.2H) , 6.9-7.6 (q,4H), 5.4 (s,0.6H), 4.2 (s,2H); NMR (D20):
(q,4H), 5.6 (s,lH),

4.3 (s,2H),

4.0 (H20)?

Xmax=262nm,

9.2

&-

5 =7.1-7.8

e262=~15'800

M^cm”1. A sample was recrystalized twice from ethylacetate and determined
to be the monohydrate by elemental analysis.
mass spectrum, m/e (relative intensity):

Anal. (CgHgBrC^) C,H,Br.

El

197,199(M+-CHO, 100), 169,171

(M+~COCHO,5), 147(M+-Br,10), 118(M+-Br-CHO, 100), 90 (M+-Br-OOCHO, 100).

p-Fluoromethylacetophenone —

p-Fluoromethylacetophenone was

synthesized from p-bromomethylacetophenone using a fluorinated resin (127).
The anion exchange resin (1 kg? Sigma, Amberlite IRA-900; Chloride) was
first converted to the hydroxy-form by washing it with IN NaOH (3 liters)
followed by warm distilled H20 (~10 liters) until the wash solution pH
turned ~7.0.

In a completely glass-free aparatus, the resin was then

converted to the fluoride-form by washing it with 1 M hydrofluoric acid
(2.5 liters) followed by washings with H20 (~15 liters) until washings
reached near neutral pH.

The resin was then washed with 95% EtOH (~1

liter) and then with benzene C250 ml).

The resin was dried overnight in a

dessicator under vacuum, then rotovapped.

A portion of this partially

dried resin (250 g) was suspended in dry benzene (previously dried over
sodium metal, distilled, and then stored over molecular seives) for
additional dehydration which was performed by refluxing it for 24 hrs in a
Soxhlet extractor containing molecule sieves.
by vacuum and low heat.

The benzene was then removed

The fluorinated resin (64 g; 3.4 mequiv.

was suspended in 375 ml of pentane.

F~/gram)

p-Bromomethylacetophenone (5.7 g;

0.027 moles) was added and the vigorously mixed solution was slowly heated
to reflux and left refluxing for ~2 days.

The liquid was decanted off the

resin and concentrated under reduced pressure to yield 0.35 g (9%) of
product.

Ether washings of the resin resulted in the collection of 0.5 g

32

(12%) of product.

Methylene chloride washings (total of 400 ml) yielded

2.4 g (59%) of desired product, NMR (CDCI3):
(s,0.7H), 5.0 (s,0.7H), 2.5 (S,2.9H).

5

=7.2-8.0 (q,4H), 5.8

The combined samples were distilled

under reduced pressure to yield 1.8 g (overall yield 45%) of >95% pure pfluoromethylacetophenone, bp 45°C (0J. mmHg), NMR (CDCI3):
4H), 5.8 (S,1H), 4.9 (s,lH), 2.5 (s,3H)

5

=7.2 - 7.9 (q,

Anal. (C9H9FO) C,H.

p-Fluoromethylphenylalyoxal - (The proper name is 4-fluoromethyl- a oxo-benzeneacetaldehyde).
as the bromo-analog.

This compound was synthesized in the same manner
Thus, fluoromethylacetophenone (0.95 g;

0.0063

moles), selenous acid (0.84 g; 0.0065 moles), and dioxane (5 ml) were
reacted under argon gas for 2 hrs.

The crude reaction product was then

purified on a 55 gram silica gel column (inner diameter = 2.2 cm; length =
50 cm).

The desired product, p-fluoromethylphenylglyoxal-monohydrate,

eluted with a 35% hexanes and 65% ethylacetate solution in 60% yield,

mp.

120-122°C,

5.3

NMR

(acetone-dg,

poorly soluble):

(s,0.7H), 5.0 (1.6,H), 4.5 (s,0.7H).

X max=253,

5 =6.8-7.7

(q,4H),

e253=~12'400 M”1cm”1.

Anal. (C9H9F03) C,H.

B. ENZYMATIC METHODS

All pH measurements were determined with an Orion Research model 601A
Digital Ionalyzer equipped with an Orion Research Semi-micro Combination pH
Electrode.

Enzymatic reactions were usually carried out in a 0.05 to 0.2M

potassium phosphate buffer at a pH between 6.0 to 7.5.
GSH concentrations ranged between 0.1 to 2.0 mM.

Ketoaldehyde and
Glyoxalase I

[S-

lactoylglutathione methylglyoxallyase (isomerizing) EC 4.4.1.5 (Sigma,
Yeast, Grade X)] was commonly used at 1 to 3 units per ml of reaction
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mixture where 1 unit is defined as the amount of enzyme which will convert
1.0 umole of substrate to product per minute at pH 6.6 at 25 °C.

Glyoxalase

II [S-2-hydroxyacylglutathione hydrolase EC 3.1.2.6 (Sigma, Beef liver)]
was used at 0.5 to 1.5 units/ml of reaction mixture where 1 unit is defined
as the amount of enzyme that would hydrolyze 1.0 umole of
lactoylglutatione per minute at pH 7.4 at 25°C.
observing

the

decrease

in

absorbance

S-

Reactions were followed by
of

the

halogenated

methylphenylglyoxals at the noted wavelengths on a Beckman Model 35
Spectrophotometer.

Conditions of individual enzymatic experiments,

including inhibition studies are reported in detail in the Results Section.
Attempts were made to identify the products of the enzymatic reactions by
both purification of the reaction mixture by passage through a Dowex-1
formate column and by high pressure liquid chromatography.

These samples,

as well as actual enzymatic reaction mixtures were analyzed on a Bruker WM
500-MHz NMR Spectrometer.

Fluoride ion and bromide ion release were

followed with an Orion Research Digital Ionalyzer (Model 601A) equipped
with either an Orion Fluoride Electrode (Model 96-09) or an Orion Bromide
Electrode (Model 94-35).

Ketoaldehyde Stock Solution - Example of preparation:

A stock 50 mM

bromomethylphenylglyoxal-monohydrate solution would be prepared by
dissolving 5.1 mg (0.021 mmoles) of compound in 420 ul of methanol or
ethanol.

Typical enzymatic reactions were run at a ketoaldehyde

concentration of 0.2 mM.

Therefore, 4 ul of stock solution would be added

to a 1 ml aqueous reaction mixture.

GSH Stock Solution - Because glutathione is easily oxidized, GSH
solutions were kept cold and prepared fresh daily.

A stock 50 mM GSH

solution was prepared by dissolving 15.4 mg (0.05 mmoles) glutathione
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(Sigma) in 1000 ul water.

Typical enzymatic reactions had an equimolar to

a ten times excess of GSH based on the ketoaldehyde concentration.

1. Enzyme-Substrate Studies

Spectrophotometric Studies - The halogenated methylphenylglyoxals were
studied as substrates of the glyoxalase enzyme system.

Reactants were

mixed in a spectrophotometer cuvette (either 10 mm or 3 mm UV path length)
in order to follow the course of the reaction spectrophotometrically.
Thus, to a 3 mm path cuvette containing 974 ul of pH 6.0, 0.1 M potassium
phosphate buffer,

8

ul of 46 mM stock substrate solution (final reaction

concentration = 0J7 mM) and 16 ul of 51 mM stock solution (final reaction
concentration = 0.8 mM) were added.

The reaction was then followed

spectrophotometrically with no enzyme present, with glyoxalase I

(1

unit/ml

of reaction mixture), or with glyoxalase I (1 unit/ral) and glyoxalase II
(0.5

unit/ml

of

reaction

mixture).

fluoromethylphenylglyoxal were followed at

Reactions
*=256nm.

containing

p~

Reactions containing

p-bromomethy lphenylglyoxal were followed at A=262nm.

Hiah

Resolution

HME

S.kll4ii£.£

- The

reactions

of

p-

bromomethylphenylglyoxal and GSH with the glyoxalase enzyme system were
also followed by high resolution NMR.

Reactions were carried out in an NMR

tube containing buffer made with deuterated water and analyzed with
MHz NMR spectrometer.

a 500

Bromomethylphenylglyoxal (3.2 mg, 0.013 mmoles) was

disolved in 100 ul of deuterated methanol (CD3CD2OD).

A 200 mM GSH

solution was made by dissolving GSH (30.8 mg, 0.1 mmoles) in 500 ul of
deuterated water.
solution,

20

To 564 ul of a pD 6.1, 0.05 M potassium phosphate

ul of the p-bromomethylphenylglyoxal

solution

(final

concentration in reaction mixture = 4.4 mM) and 14 ul of the GSH solution
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(final concentration in reaction mixture = 4.8 mM) was added and an NMR
spectrum of the formation of the thiohemiacetal was recorded.

Addition of

2 ul of a glyoxalase I solution containing 5 units/ul of solution (final
concentration of enzyme in reaction mixture =“17 units/ml) resulted in the
conversion of the thiohemiacetal to its corresponding thioester.

Isolation gf Products fox High Resolution NMR — Attempts were made to
isolate the products of the reaction of p-bromomethylphenylglyoxal and GSH
in the presence of glyoxalase I and II.

Thus, to a pH 6.0, 0.1 M potassium

phosphate buffer (30 ml), GSH (61.1 mg, 0.2 mmoles) was added.
pH fell to 4.7, 1 N NaOH was added to raise the pH to 6.0.

Because the
Glyoxalase I

(120 ul, 60 units), glyoxalase II (120 ul, 12 units), and a methanol
solution of

p-bromomethylphenylglyoxal (24.2 mgy 0.1 mmoles in 200 ul

MeOH) was then added and the reaction mixture was reacted for 1 hr under an
argon atmosphere.

The reaction mixture was then loaded onto a Dowex-1

formate column (outer diameter = 1.3 cm; length = 50 cm) at 3KC.

The

product was eluted off the column with a 0 to 6 M formic acid linear
gradient (400 ml + 400 ml).

Fractions of “5 ml were collected by an

automatic fraction collector.

The presence of a product in a fraction was

identified by measuring the absorbance of each fraction on a Beckman DU
Spectrophotometer (Model 2400) at X=266 nm.

The fractions which contained

product were combined and concentrated under reduced pressure.

Before NMR

analysis was performed, the sample containing product was washed numerous
times with D20.

High pressure liquid chromatography (HPLC) was used to further purify
the major product found by Dowex-1 formate column chromatography.

The

concentrated solution was placed on a Alltech HPLC Column (Cat. #8250; Frit
size:

2 u; inner diameter = 4.6 mm; length = 25 cm; packing material:
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Partisil 10 ODS2, size 10 u) in 50 ul alliquots and eluted with distilled
water. The major peak detected by a Gilson UV Spectrophotometer at *=266 nm
was collected by numerous injections of the concentrated material from the
Dowex-1 formate column onto the HPLC column.

The combined samples were

concentrated under reduced pressure, washed numerous times with deuterated
water, and then analyzed by high resolution NMR.

2. "Inverse" Substrate Studies

Spectrophotometric Studies — p-Bromomethylphenylglyoxal was tested as
an

inverse

substrate

of

glyoxalase

bromomethylphenylglyoxal-monohydrate was

I.

Thus,

0.3

mM

p-

incubated with an equimolar

amount of GSH at pH 7.5, 0.1 M potassium phosphate buffer for 3 to 6 hours
under an argon atmosphere.

The pH of this solution was then adjusted to a

pH 7.2 by adding to it an equal volume of pH 7.0, 0JL M potassium phosphate
buffer.
solution.

Glyoxalase I (1 unit/ml of reaction mixture) was added to this
(Any thiohemiacetal of p-bromomethylphenylglyoxal and GSH which

had inadvertently formed was converted to its corresponding thioester and
would undergo no further reactions.)
either GSH (334 mM) or ethanethiol

Then, a ten times molar excess of
(334 mM; EtSH) was added.

were followed by measuring the change in absorbance at

Reactions

*=260nm.

After

observing any reaction for half an hour, an additional ten times excess of
ethanethiol was added to the mixture already containing ethanethiol,
followed by the addition of an excess of GSH.

Reactions were continuously

followed spectraphotometrically as noted above.

Isolation of Products for High Resolution NMR - The product of the
"inverse" substrate reaction of p-(glutathio-methyl)phenylglyoxal and
excess GSH with glyoxalase I and II was isolated and identified by high

I
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resolution NMR.

To a

7.5, QJ. M potassium phosphate buffer (30 ml), GSH

(120.9 mg, 039 mmoles) and p-bromomethylphenylglyoxal-monohydrate (22.8
mg, 0.09 mmoles in 200 ul of MeOH) was added and allowed to react at room
temperature for ~2 hours.

Glyoxalase I (60 units) and glyoxalase II (12

units) was then added and allowed to react for ~1 hr.

This reaction

mixture was then pumped onto a Dowex-1 formate column (outer diameter = 13
cm; length = 50 cm) at 3°C.

A 0 to 6 M formic acid linear gradient (400 ml

+ 400 ml) was used to elute the products off the column.
ml were collected by an automatic fraction collector.

Fractions of “5
The presence of a

product in a fraction was identified by measuring the absorbance of each
fraction on a Beckman DU Spectrophotometer (Model 2400) at

A =266 nm.

The

fractions that revealed the presence of a product were combined,
concentrated under reduced pressure, and then washed numerous times with
deuterated water.

3. Enzyme Inhibition Studies

An initial simple screening stud/ was first carried out to determine
if p-bromomethylphenylglyoxal would inhibit glyoxalase I activity.

The

initial

mM

velocity

of

the

enzymatic

reaction

of

0.12

bromomethylphenylglyoxal and 2 mM GSH was observed with 0.5 units
glyoxalase I/ml of reaction mixture.

With the addition of more

bromomethylphenylglyoxal, a new initial velocity was observed.

As a

control, an identical procedure was carried out with 0J.2 mM phenylglyoxal.

A more detailed and rigorous study of the irreversible inhibitory
effect of p-bromomethylphenylglyoxal on glyoxalase I was performed by
incubating p-bromomethylphenylglyoxal (at 0.02, 03, and 2.0 mM) with two
equivalents of GSH in the presence of 25 units glyoxalase I/ml of reaction
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mixture in a pH 5.5, 0.1 M acetate buffer.

At various time points an

aliquot from this inhibition reaction mixture was added to an assay
solution containing 0.4 mM methylglyoxal, 2 mM GSH in a pH 6.6, 0.1 M
potassium phosphate buffer.

The calculated enzyme concentration in this

assay mixture after the transfer was "0.1 units glyoxalase I/ml of
solution.

An initial velocity of the conversion of the thiohemiacetal of

methy lglyoxal to its corresponding thioester was measured by following the
change in absorbance at X =240nm.
which

the

"inhibitor

Control experiments included a run in

reaction

mixture"

contained

no

p-

bromomethylphenylglyoxal, but contained the proper amount of ethanol (the
solvent p-bromomethylphenylglyoxal was dissolved in).

A second type of

control study, which contained no GSH in the inhibitor reaction mixture,
was run at each inhibitor concentration.
inhibition.

This would reveal non-enzymatic

A third type of "control" allowed the formation of the inverse

substrate, p-(glutathiomethy Dphenylglyoxal.

This involved the pre¬

incubation of p-bromomethylphenylglyoxal and GSH for 45 minutes in a pH
7.5, 0.1 M potassium phosphate buffer.

To this solution, glyoxalase I was

added and inhibition was followed as above.

4. Methods of Measuring Ion Release

Fluoride Ion Release - Fluoride release was determined following
procedures outlined in the fluoride electrode Instruction Manual (128).
glass free apparatus was used.

A

A calibration curve was made by mixing

commercial standard samples (Orion) of known fluoride ion concentration
with an equal volume of potassium phosphate buffer.

Fluoride release

during the enzymatic reactions (2 mM GSH, 0.5 mM fluoride substrate,
glyoxalase I, 3 units/ml reaction mixture, glyoxalase II, 0.6 units/ml
reaction mixture in 1000 ul of pH 6.0, 0.1 M potassium phosphate buffer)
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was followed continuously using the fluoride ion electrode.

Side by side

controls were run using fluoromethylglyoxal, a known fluoride eliminating
compound (96).

Bromide ion Release - Bromide ion release was followed using modified
procedures outlined in the bromide electrode Instruction Manual (129).
Because of the bromide electrode's marked sensitivity to free thiols in
solution (i.e. GSH), it was necessary to eliminate any free thiols before a
bromide ion determination was performed.

This involved stopping the

enzymatic reaction by adding an excess of N-ethylmaleimide (NEM) which is
known to react with free GSH (130,131) and thus protected the electrode
from poisoning by free sulfhydryls.

Calibration curves were made by mixing

commerical standard samples (Orion) of known bromide ion concentration with
an equal volume of potassium phosphate buffer containing GSH (ImM) and NEM
(5mM).

Bromide release during enzymatic reactions, run at the usual

compound concentrations

(i.e.

2 mM GSH,

0.5 mM bromide substrate,

glyoxalase I, 3 units/ml, glyoxalase II, 0.6 units/ml in pH 6.0, 0.1 M
potassium phosphate buffer), was measured with the bromide electrode by
taking alliquots from the reaction mixture then adding it to a solution
containing a five times excess of NEM.
as a control.

Bromomethylglyoxal (132) was used

Because one was limited by the time it took for each bromide

ion determination, a further modification of the procedure allowed the
rapid time course of the reaction to be followed.

This was done by

removing 500 ul of the reaction mixture at the desired time points and
adding it to 5 ul of 30% nitric acid.

This lowered the solution's pH to

2.5, a level that inactivated both glyoxalase I and II.

Bromide ion

release was then measured with the electrode by taking this solution and
adding it to an equal volume of a potassium phosphate buffer at pH 8.0,
thus making the pH of the resulting solution 6.8.

The GSH in solution was
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then immediately "inactivated" by adding a five-times molar excess of NEM
before a bromide reading was taken.

Calibration curves for this type of

experiment were generated by adding a buffer solution which had undergone
identical modifications to the standard samples of known bromide ion
concentration.

Five types of bromide elimination studies were performed.

Three experiments were controls in which bromide ion measurements were
taken on bromomethylphenylglyoxal alone, bromomethylphenylglyoxal with GSH,
and bromomethylphenylglyoxal with glyoxalase I.

The two other experiments

performed were with bromomethylphenylglyoxal and GSH in the presence of
glyoxalase I and in the presence of glyoxalase I and II.

C. TISSUE CULTURE METHODS

Standard tissue culture experiments were run on P388 and L1210 mouse
leukemia cell lines.

The cells were maintained in suspension culture at

37°C in a 5% CO2 humidified atmosphere.

Three times per week, 105 cells/ml

were passed in PRMI 1640 medium supplemented with 10% beef inactivated
fetal calf serum (GIBCO),

streptomycin (100 ug/ml), penicillin (100

units/ml), and 1% glutamine (100 mM).

Agents were added 24 hours after

c

seeding (10
days.

cells/ml).

Cell counts were taken every 24 hours for three

Agents tested were run at approximately, 10“4, 10 ”5, and 10“6 M.

The compounds used were of highest purity available.

Standard solutions

for this set of experiments were made by first dissolving the desired
compounds in methanol to make a 50 mM solution.

The appropriate volume was

then added to 5 ml H2O to make a 10”^ M solution.
were:

methylacetophenone,

fluoromethylacetophenone,

The compounds tested

p-bromomethylacetophenone,

phenylglyoxal,

p-bromophenylyglyoxal,

bromomethylphenylglyoxal and p-fluoromethylphenylglyoxal.

pp-

-
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a BIOLOGICAL TEST METHODS

The newly synthesized halogenated methylphenylglyoxals were evaluated
for their anti-cancer activity against L1210 tumor bearing mice following
previously described procedures (133).

L1210 ascites cells were withdrawn

from the peritoneal fluid of donor CDF^ mice bearing 7-day growths.

The

suspension was centrifuged for 2 minutes, the supernatant decanted, and a
10 fold dilution with isotonic saline was made.

The cell number was

determined with a Coulter particle counter, and the cell population was
adjusted to 106 cells/ml.

0.1

ml

(containing

Transplantation was then performed by injecting

approximately

intraperitoneally into each animal.

105

cells)

of

this

solution

The test compounds were administered

by intraperitoneal injection, beginning 24 hours after tumor implantation
followed by once daily injections for a total of 6 consecutive days.

The

test compounds were injected as fine suspensions following homogenization
in 2 to 3 drops of 20% aqueous Tween 80 and then made up to the proper
volume with isotonic saline.

All test compounds were administered

intraperitoneally in a volume of 0.5 ml.
compounds

were

carried

out

Anti-cancer activity of the test
at

various

concentrations.

Bromomethylphenylglyoxal was tested at 1, 2.5, 5, 10, 25 and 50 mg/kg.
Fluoromethylphenylglyoxal was tested at 10 and

50 mg/kg.

For any one

experiment, the mice were distributed into groups of 5 of comparable
weight.

Throughout the experiment, the mice had unlimited access to Purina

Laboratory Chow pellets and water.

Control tumor-bearing animals were

given injections of comparable volumes of the vehicle solution not
containing any test compound.
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RESULTS

A. Synthesis of Halogens ted Methylphenylglyoxals
Brcmo- and fluoromethylphenylglyoxal were successfully synthesized
from p-methylacetophenone.

Methylacetophenone was selectively brominated

with N-bromosuccinimide to yield p-bromomethylacetophenone.
was

either

directly

oxidized

with

selenous

This compound
acid

to

p-

bromomethylphenylglyoxal or fluorinated with an ion-exchange resin to yield
p-fluoromethylacetophenone.

The fluorinated compound was then oxidized

with selenous acid to p-fluoromethylphenylglyoxal.

Both compounds were

positively identified by NMR analysis and elemental analysis.
compound was also identified by mass spectroscopy.

Hie bromo-

For details of

syntheses and analyses see the Materials and Methods section.

B. Balomethylphenylglyoxals:

A Si±)6trate of Glyoxalase I and II

Bromo- and fluoromethylphenylglyoxal were found to be substrates of
glyoxalase I and II.

At enzymatic reaction conditions of 0.37 mM

bromomethylphenylglyoxal and two equivalents of GSH at pH 6.0 one could
follow the rate of the reaction spectrophotometrically by observing the
decrease in absorbance at
( X max=262 nm;

X =260 nm.

Hie conversion of the thiohemiacetal

e262=~^4'30^ M-1cm“^) of bromomethylphenylglyoxal and GSH

to its corresponding thioester ( Xmax=234; e 2g2=~3rl00 M“^cm-1) was enzyme
dependent and could be accelerated by the presence of glyoxalase II.
Table 1).

(See

This was most likely due to the regeneration of GSH which

results in a higher concentration of the thiohemiacetal which is the
substrate of glyoxalase I.

At identical enzymatic reaction conditions the

rate of the enzymatic conversion of the thiohemiacetal ( X max=252 nm) of
fluoromethylphenylglyoxal

and

GSH to

its

corresponding

thioester
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Table 1:

Glyoxalase I

Glyoxalase II

Velocity (oo/min)
BrMe^G1

FMec(>G2

-

0.81

0.44

1

0.5

0.77

0.47

1

1.5

1.00

3

-

0.95

3

1.5

1.13

(Unit/ml)

(Unit/ml)

1

1

BrMe4>G:

Brcrronethylphenylglyoxal

FMe4>G:

Fluoranethylphenylglyoxal

(0.37mM)

2

(0.3 3mM)

(£256=”2,500 M^cm-1) appeared slower than that of the bromo-compound. At
A=256 ran, the initial velocity of the glyoxalase I (1 unit/ml of reaction
mixture) catalyzed conversion of fluoromethylphenylglyoxal to its thioester
was 0.44 O.D./minute.

In the presence of glyoxalase I (1 unit/ml) and

glyoxalase II (0.5 unit/ml of reaction mixture) the velocity was only
slightly higher at 0.47 O.D./minute.

C. p-BronKxnetjhylphenylglyoxal as a Precursor of an "Inverse" Substrate
It was noted that p-bromomethylphenylglyoxal and GSH underwent a time
dependent change in absorbance at
potassium phosphate buffer.

A=

262 ran when mixed in a 01 7.2 to 7.5

After about 80 minutes, no further significant

drop in absorbance was noted.

This suggested that at high pH, GSH was

attacking bromomethylphenylglyoxal at the reactive brominated benzylic
carbon forming glutathiomethylphenylglyoxal (XXTV)

[\

This was

first shown enzymatically by adding glyoxalase I to a previously incubated
mixture of approximately equimolar bromomethylphenylglyoxal and GSH.
change in absorbance noted at

A = 260 ran

The

was about less than a third of
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the expected change in absorbance of enzymatic reactions at lower pH.

This

revealed that much of the GSH was in a form which prevented the formation
of the thiohemiacetal.
the benzylic carbon.

It appeared that the GSH was covalently attached to
To test if p~glutathiomethylphenyiglyoxal could act

as an "inverse" substrate of glyoxalase I, excess ethanethiol (EtSH) was
added to the mixture to form the thiohemiacetal (XXVb).

This activated the

Ol hydrogen making it acidic and allowed for potential proton abstraction
by the active site base via inverse chemistry .
glyoxalase I, no change in absorbance was noted.

In the presence of

However, when excess GSH

was added, a large change in absorbance was noted, consistent with a
typical glyoxalase I catalyzed reaction forming the corresponding thioester
( e262“~3'500 M”1cm“1).

At roughly 0.11 mM glutathiomethylphenylglyoxal

and 10 equivalents of GSH the initial velocity of the glyoxalase I (1
unit/ml) catalyzed reaction was

0J.4 CUVmin.

When excess GSH was added

to the reaction mixture containing ethanethiol, there was a typical change
in absorbance noted, however, the initial velocity of the conversion of the
thiohemiacetal to the thioester was about half the rate noted above.

This

finding was consistent with the competition of GSH and EtSH to form the
thiohemiacetal of glutathiomethylphenylglyoxal.

In this case, GSH must

form the thiohemiacetal for processing by glyoxalase I.

(See Figure 3).

Thus while p-bromomethylpherrylglyoxal forms glutathiomethylphenylglyoxal,
it does not undergo "inverse" substrate processing by glyoxalase I.
However, the glutathione substituted methylphenylglyoxal does undergo
enzymatic processing in the presence of excess glutathione.
proof

of

the

above,

the

reaction

product

As further
(XXYD

of

glutathiomethylphenylglyoxal, excess GSH, and glyoxalase I and II was
isolated by Dowex-1 formate column chromatography (first of two peaks;
eluting at 1M formic acid) and identified as the proper product by high
resolution NMR (See Figure 4).
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Figure 5:

Glutathiomethylphenylglyoxal1 as a Substrate of Glyoxalase I2

TIME (MIN)

1Glutathionethylphenylglyoxal was formed by incubating brcmomethylphenylglyoxal (0.29mM) and GSH (0.3mM) for greater than
3 hours in a 0.1M potassium phosphate buffer at pH 7.5 under
argon gas.
2 After formation of the glutathicmethylphenylglyoxal, the
solution was added to an equal volume of 0.1M potassium
phosphate buffer at pH 7.0 (the final solution's pH = 7.2).
Reactions were followed at X = 260nm by first adding glyoxalase
I (1 Unit /ml reaction mixture) to react with any excess GSH,
then by adding the proper amount of thiol.
3AA = Change in Absorbance = Absorbance - Initial Absorbance.
‘‘Control experiment containing approximately an identical
concentration of phenylglyoxal in a 0.1M potassium phosphate
buffer at pH 7.2, along with GSH (1.5mM) and Glyoxalase I
(1 Unit/ml).
5Reaction mixture with excess GSH (1.5mM) .
6Reaction mixture initially with excess ethanethiol (EtSH)
(1.5mM) , then with excess GSH (1.5mM) .
7Reaction mixture with excess EtSH (1.5mM).
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Figure 4:

Formation of the "Inverse" Substrate and Identification
of the Enzymatic Product by Vi - nmr

-C0CH0

Br-CH2-

+

1

eq.

GSM

xv
pH 7.5
-C0CH0 + BR

gs-ch2xxiv

GLY I

No

Reaction

xxvi

a:
f:
i:

7.2(q,4H),b: 5.0(s,lH),
3.5 (s,2H) , g: 2.7(q,lH),
1.9-2.0(m,2H).

c:
g:

4.2(q,lH), d,e:
3.7-3.9(3H),
2.5(q,lH),h: 2.1(m/2H),
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D.

Fluoride Release ty Fluorcmetbylphenylglyoxal?
Under typical enzymatic reaction conditions with glyoxalase I alone or

with both enzymes present, absolutely no fluoride ion elimination was
observed for fluoromethylphenylglyoxal.

(However, as shown previously,

this compound was determined to be a substrate for glyoxalase I).

No

fluoride ion release was noted at a pH range of 6.0 to 7.3 or after
extended

reaction

times

of

greater

than

60

hours.

Thus,

p-

fluoromethylphenylglyoxal, while acting as a substrate of the glyoxalase
enzyme

system,

does

not

eliminate

fluoride

ion.

Nor

does

p-

fluoromethylphenylglyoxal undergo attack by GSH at the benzyl ic carbon to
form glutathiomethylphenylglyoxal.

Control experiments studying fluoride

ion release using fluoromethylglyoxal confirmed previously published
results (96).

Thus, at pH 6.0 and 7.3, total fluoride release was observed

when fluoromethylglyoxal and GSH were incubated at standard reaction
conditions with glyoxalase I only.

When glyoxalase I and II were present a

single burst of fluoride release was detected.

The ratio of fluoride

released to total fluoride was 0.35 which agrees with the previously
published partitioning ratio of 0.32 for fluoromethylglyoxal - yeast
glyoxalase enzyme system (96).

E.

Bromide Release by BraDanethylphenylglyoxal
The bromide ion release experiments were fraught with many

methodological problems, some which remain unresolved and therefore prevent
quantification of

results.

The

first problem of the bromide

ion

electrode's sensitivity to GSH was nicely overcome by quenching the
reaction with N-ethylmaleimide before reading were taken.

This procedure

reproducibly eliminated the GSH from causing incorrect Br~ release
measurements.

The unresolved problem which prevented the quantification of

data was the apparent instability of the tested compounds in the presence

'

48

of the bromide electrode.

Thus, when one of the bromide containing

compounds was present with the bromide electrode, a reading could be
obtained showing bromide release.

A second measurement of the same sample

would show further bromide release.

However, what can be preliminarily

reported is the finding the p-bromomethylphenylglyoxal affords a
substantial amount of bromide ion released which is enzyme catalyzed (See
Figure 5).

The expected trends are seen.

The glyoxalase I catalyzed

reaction appears to be on a path which would lead to total Br~ elimination.
The glyoxalase I and II catalyzed reaction exhibited a burst of bromide
release, but then no further release is measured.

And, at pH 6.0 and a two

times excess of GSH, there is a slow non-enzymatic release of bromide due
to "inverse" substrate formation.

The important control studies

demonstrated little to no sponteneous bromide ion release from
bromomethylphenylglyoxal or from this compound in the presence of
glyoxalase I.

F.

Isolation of Enzymatic Products for High Resolution M®.
Many attempts were made to isolate the products of the enzymatic

reaction of bromomethylphenylglyoxal and two equivalents of GSH at pH 6.0
with glyoxalase I (2 units/ml) and glyoxalase II (0.4 units/ml).

Most

attempts at isolating the enzymatic products by Dowex-1 formate column
separation and by HPLC were unsuccessful and resulted in NMR spectra of
unsatisfactory quality.

A product which had undergone bromide elimination

could not be clearly identified.

Definitive identification of enzymatic

products such as p-bromomethylmandelic acid were unsuccessful due to the
interference of a large water signal on NMR tracings.
Subsequent work in our laboratory (135) has identified the product of
p-fluoromethylphenylglyoxal and GSH in the presence of glyoxalase I and II
as p-fluoromethylmandelic acid.

49

Figure 5:

Bromomethylphenylglyoxal — Bromide Ion Elimination1

time (min)
’■Reactions were carried out in a 0.1M potassium phosphate
buffer at pH 6.0 with braronethylphenylglyoxal at 0.4mM and
other reactants at the concentrations noted below. Analyses
were performed as described in the METHODS section.
2GSH (0.8mM); Glyoxalase I (1 Unit/ml of reaction mixture).
3GSH (0.8mM); Glyoxalase I (1 Unit/ml); Glyoxalase II (0.5
Unit/ml) .
4GSH (0.8mM); No enzymes present.
5Glyoxalase I (1 Unit/ml); No GSH present.
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G.

Identification of Enzymatic Products by High Resolution KIR
Identification of products by NMR by direct analysis of reaction

mixtures of bromomethylphenylglyoxal and GSH in the presence of glyoxalase
I yielded more definitive results.
concentrations#

At equimolar substrate and GSH

the formation of the thiohemiacetal could be observed by

following the C-l hydrogen [6.1 ppm (s, 1H)].

With the addition of GSH,

this singlet decreased in intensity as new peaks formed, indicating the
formation of the thiohemiacetal.

In the newly formed thiohemiacetal the

diastereotopic protons of the C-l hydrogen are clearly resolved.

In

agreement with the previously reported (76) chemical shifts of similar
protons of the thiohemiacetal of phenylglyoxal and GSH, two singlets of
equal intensity were observed at 6.45 and 6.48 ppm as seen in Figure 6.
Figure 6:

6,10

-C-C-SG
OH
(ppm)

In
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the presence of glyoxalase I there is total disappearance of these protons
of the thiohemiacetal, thus suggesting glyoxalase I processing of the
thiohemiacetal of bromomethylphenylglyoxal and GSH to a thioester.

The

formation of a methyl-group after protonation of the bromide elimination
product

(XXI)

was not detected by high resolution NMR.

It was also

impossible to detect accurately the decrease in the intensity of the bromomethylene peak which would suggest bromide elimination.

This was

unachievable because the nmr signal of the brominated methyl-group of the
starting material fortuitously fell at the same ppm of the H2O signal.
However, if one attempted to ignore the large interference by the water
peak, one could determine a slight decrease in the brominated methylene
signal which might have revealed that bromide elimination had occurred to
sane extent.

H.

Braaoaethylphenylglyoxal as a Glyoxalase Inhibitor
The initial test screen for enzyme inhibition by the serial addition

of bromomethylphenylglyoxal to a reaction containing greater than 15
equivalents of GSH and 0*5 units of glyoxalase I/ml reaction mixture gave
the first evidence that the compound was an inhibitor of glyoxalase I.
That is, when compared to the initial velocity of the serial additions of
phenylglyoxal to an identical reaction mixture, the addition of
bromomethylphenylglyoxal caused a continuous decrease in the initial
velocity with each subsequent additon (see Figure 7).

I.

Irreversible Inhibition of Glyoxalase I by p-Brcconethylphenylglyoxal
At a given concentration of p-broraomethylphenylglyoxal,

dependent inhibition of glyoxalase I was observed.
to follow first order kinetics (see Figure 8).

a time

The inhibition appeared

Glyoxalase I inactivation

was also found to be dependent on the concentration of inhibitor (See

\

Figure 7:

Inhibition of Glyoxalase I by Serial Addition of
Bromomethylphenylglyoxal (BrME^G)
ADDITION (#)
BRi^Ie4>G (Mfi)
GSH (mM)
GLY I (U/ML)

1
0,12
2,0

2
0.12

3
0,06

0.5

INITIAL
VELOCITY

Control Experiment with Phenylglyoxal UG)
ADDITION (#)
<J>G (mM)
GSH (MM)
GLY I (U/ML)

12
0,12
0.12

3
0.06

2,0
0.5

100%

100%
80%

INITIAL
VELOCITY

^
0.03

Figure 8:
Bromomethylphenylglyoxal:

Irreversible Inhibition of Glyoxalase I

Plot of Time versus Activity Remaining1

1 Activity Remaining was a measure of the initial velocity of the glyoxal¬
ase I catalyzed reaction of methylglyoxal (0.4mM) and GSH (2.0mM) as
described in the METHODS section.
2% Activity Remaining is defined as the change in absorbance per min.
divided by the initial measurement of the change in absorbance per min.
at time zero for each of the different reaction conditions.
3Over Control: Inhibition solution contained glyoxalase I (25 units/ml of
reaction mixture) and GSH (4mM) . No inhibitor, BrMel>G (brcmcmethylphenylglyoxal) added.
[0.02mM] Control: Inhibitor solution contained glyoxalase I
BrMe^G (0.02mM). No GSH.

(25 U/rnl);

5[0.2mM] Control: Inhibitor solution contained glyoxalase I (25 U/ml);
BrMe4>G (0.2rrt4). No GSH.
inhibition Study: BrMecfiG (0.02mM), GSH (0.04mM), Glyoxalase I (25 U/ml).
7Inverse Substrate Formation: BrMe^G (0.2mM), GSH (0.4mM) were incubated
for 45 mins, at pH 7.5 to form glutathicmethylphenylglyoxal. Then
glyoxalase I (25 U/ml) was added and inhibition was followed with time.
8[2.0mM] Control: Inhibitor solution contained glyoxalase I
BrMe<j>G (2.0mM). No GSH.

(25 U/ml);

9Inhibition Study: BrMe^G (0.2mM); GSH (0.4mM); glyoxalase I (25 U/ml).
inhibition Study: BrMe4>G (2.0mM); GSH (4.0mM); glyoxalase I (25 U/ml).
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Figure 8).

The graph of time of incubation versus the semi-log of the %

activity remaining (See Figure 9) revealed the tjy2 (inactivation) to be
approximately 9, 2.8, and 1.7 minutes at 2 x 10“^, 2 x 10“4, and 2 x 10~^ M
respectively.

The Kj,

extrapolated from the graph of

(1/inhibitor

concentration) versus (l/k^nact^) was equal to 0.078 mM
10).

(See Figure

The first control study which contained no inhibitor demonstrated

>90% of enzyme activity present throughout the time period studied.

The

controls run at varying inhibitor concentrations, but without GSH present
revealed slight enzyme inhibition, but at a much slower rate, and following
non- first

order

kineticcs.

The

inhibition

study

in which

glutathiomethylphenylglyoxal (the "inverse" substrate) was formed by
incubating 0.2 mM p-bromomethylphenylglyoxal with 0.4 mM GSH at high pH
resulted in enzyme inhibition, but at a lower level than when compared with
0.2 mM p-bromomethylphenylglyoxal which had not undergone "inverse"
substrate formation.

The inhibition observed was probably due to unreacted

p-bromomethylphenylglyoxal which had not undergone "inverse" substrate
formation at high 0!.
As expected, further work in our laboratory (135) has demonstrated
that fluoromethylphenylglyoxal does not cause irreversible inhibition of
glyoxalase I.

J.

Tissue Culture Experiments
Bromo- and fluoromethylglyoxal were tested as growth inhibitors of

L1210 and P388 cell lines in tissue culture as a preliminary test screen
for the compound's anti-cancer activity.

The results are summarized in

Figure 11 which graphs the ratio of the cytotoxic effects on tumor growth
of the test compounds to controls versus time.

Both compounds at 10“4 M

showed greater that 50% inhibition of growth of the L1210 cell line at 24
hours when compared to controls.

Growth was shown to be further inhibited
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Figure 9:
Bromomethylphenylglyoxal:

Irreversible Inhibition of Glyoxause I

PLOT OF TIME VERSUS THE SEMI-LOG OF ACTIVITY REMAINING

ACTIVITY
REMAINING
(%)

TIME OF INCUBATION (MIN)

m

a

<inact

a

i/m

(mM)

(mM 1)

0.02

^inact

l/<-inact,
'

(min)

(min

50

9.0

0.077

13.0

0.2

5

2.8

0.248

4.0

2.0

0.5

1.7

0.408

2.6

0.693/TT

)

(min)
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Figure 10:
Bromomethylphenylglyoxal:

Irreversible Inhibition of Glyoxalase I

PLOTaOF lAinact VERSUS l/III

^lot of best line by linear regression.
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Figure 11:
Tissue Culture Experiments

P388
10 0

kMETHYU\CETOPHENONE nf)-4 m\
np-bromoacetophenone

8 0

Vluoromethylacetophenone (10-4 M)

6 0

h

%

M\

nbromomethyu\cetophenone (10 4

CONTROL 40
2 0

24

48

72

TIME (HRS)

8 0

6 0

%

CONTROL 40
2 0

TIME (HRS)

TIME (HRS)

□210
Fluormethylphenylglyoxal

BROr'IOMETHYLPHENYLGLYOXAL

10 0

8 0

%

60

CONTROL
4 0

2 0

2 4

4 8

TIME (HRS)

72

24

48

TIME (HRS)

72
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by 72 hours to levels of 60% for fluoromethylphenylglyoxal and "80% for
bromomethylphenylglyoxal.

Against

the

P388

cell

line,

fluoromethylphenylglyoxal at 10“4 M showed no more than a 40% growth
inhibition.

Bromomethylphenylglyoxal at 10”4 M resulted in ~70% cell

growth inhibition at 72 hours.

The experiments which tested cell growth

inhibition of p-methylacetophenone, p-bromoacetophenone, and pfluoromethylacetophenone resulted in no significant inhibition.
Bromomethylacetophenone resulted in ~40% cell growth inhibition at 72 hours
when compared to controls.

This was most likely due to impurities present

in the p-bromomethylacetophenone solution.

K.

Biological Evaluation in Timor-Bearing Mice
Hie halogenated methylphenylglyoxals were further evaluated for anti¬

cancer activity against LI210 tumor bearing mice.

Hie compounds were given

on 6 consecutive days at the same dose beginning 24 hours after
intraperitoneal tumor implantation.

The results are summarized in Table 2.

Fluoromethylphenylglyoxal, at a dose of 10 mg/kg and 50 mg/kg showed no
significant antineoplastic activity in this system and showed no toxicity
at the doses tested.

However, bromomethylphenylglyoxal was very potent and

showed extreme toxicity at 25 mg/kg and 50 mg/kg with all mice (tying within
24 hours after the first dose was given.

Lesser toxicity was seen

at

doses of 5 mg/kg and 10 mg/kg, with all mice surviving the 6 consecutive
treatments, but then all (tying before the untreated controls C (T/C) % less
than 100%].

There was no significant anti-cancer activity observed at

doses of bromomethylphenylglyoxal at 1.0 mg/kg and 2.5 mg/kg.

Table 2:

Biological Test of Halogenated Methylphenylglyoxals
in Tumor-Bearing Mice1
DOSE

(mg/kg)
BrME4>65

FTfeG6

NO. OF
INJ,2

TUMOR EVALN,3 4 L1210
(T/C) *
(test/control)

50

1

2.0/8.8

23

25

1

2.0/8.8

23

10

6

6.8/8.8

77

5

6

8.4/8.8

95

2.5

6

9.8/8.8

no

1.0

6

9.2/8.8

105

50

6

8.8/8.8

100

10

6

9.4/8.8

107

■'‘Compounds were injected intraperitoneally as suspensions
24 hours after a standard inoculum of 105 L1210 lymphoid
leukemia cells were implanted in CDFi mice.
Five mice
were in each test group.
2Number of injections given once daily at the same dosage
level.
3Mean survival time of animals in days.
4(T/C)% is the ratio of the mean survival time of treated
animals to control animals expressed as percent.
In
general, a decrease in survival time of treated animals
as compared to control animals resulting in a (T/C)% of
less then 100% reflected drug toxicity.
5BrMe<J>G:
6FMe<J>G:

Bromomethylphenylglyoxal
Fluoromethylphenylglyoxal
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DISCUSSION

Novel halogenated keto-aldehydes were successfully synthesized in high
yield.

The basis for their design was to synthesize a substrate for

glyoxalase I that might, when activated by the enzyme, form a highly
reactive compound that would be susceptible to Michael addition by a
nucleophile at the active site.

Such a strategy would create a covalently

linked compound in the active site, thus inactivating the enzyme.

This

scheme, which proceeds via halogen elimination, provides further evidence
that the glyoxalase I mechanism proceedes through a fast-shielded proton
transfer and not by a hydride shift.

The newly synthesized compounds were

also tested as possible "inverse" substrates of glyoxalase I.
Like other halogenated methylglyoxals described by Kozarich (99) which
form "inverse" substrates of glyoxalase I, bromomethylpherrylglyoxal was
found to react non-enzymatically with GSH at high pH forming pglutathicmethylphenylglyoxal.

This could be observed by the slow change in

IN absorbance, as well as by the slow elimination of bromide ion detected

by the bromide electrode.

This type of reaction was not observed when

fluoromethylphenylglyoxal was incubated under identical conditions with
GSH.

This might be expected because the fluoride ion is not as a

sufficiently good leaving group when compared to the bromide ion.

However,

when the uniquely formed glutathiomethylphenylglyoxal was incubated with
glyoxalase I and ethanethiol, which renders the former aldehydic proton
acidic and thus potentially susceptible to proton abstraction by the active
site base, no enzymatic reaction was observed.

This is in marked contrast

with glutathiomethylglyoxal which Kozarich & Chari (99) found to undergo
inverse substrate processing.

Because glutathiomethylphenylglyoxal was

unreactive in the inverse reaction, this suggests, as we recently reported
(134), that there is a constraint on the distance and geometry between the
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glutathione moiety and the a -keto-aldehyde in the inverse reaction (See
Figure 12).

However, when glutathiomethylphenylglyoxal was incubated with
Figure 12:

excess GSH,
corresponding

glyoxalase I successfully

converted it to

its

a-hydroxythioester which, in the presence of glyoxalase II,

was hydrolyzed to the hydroxy acid.

Hiis product was successfully isolated

and identified by high resolution NMR. The processing of the thiohemiacetal
of glutathiomethylphenylglyoxal and GSH by glyoxalase I provides an
additional example of the requirement of glyoxalase I for GSH for binding
and

the

enzyme's nonspecificity for the

a-keto-aldehyde.

In this case,

a methylphenylglyoxal with a tripeptide side chain was successfully
processed by glyoxalase I and II.

This might indicate the ability of the

glyoxalase system to process large macromolecules containing keto-aldehyde
side chains.

Such a proposition could be significant in yet to be

discovered important intracellular substrates which might be key to the
definitive physiological function of glyoxalase.

62

The findings that the thiohemiacetals of brorao- and fluoromethylphenylglyoxal and GSH are substrates of glyoxalase I are similar examples
of the non-specific nature of glyoxalase for the
highly specific nature of its binding to GSH.

a-keto-aldehyde and the
As can be expected, the

thiohemiacetal of bromomethylphenylglyoxal and GSH was found, by high
resolution NMR, to form two stereoisomers (76,77).

Hiese two isomers are

presumed to undergo equal processing by glyoxalase I (in the presence of
enzyme, both disappear).
identified.

Hie newly formed thioester was not successfully

Of equal disappointment was our inability to identify, by NMR,

the product of the enzymatic elimination of bromide.

The possibility,

however, remains that our attempts to identify the protonated intermediate,
XXI. were unsuccessful because the quinoid-like intermediate, XIX. diffused
out of the active site and was immediately attacked by a nucleophile (e.g.
GSH) forming XXII.

No attempts were made to isolate this product.

And,

because of the presence of GSH in the reaction mixture, such a product
could not be easily identified by direct analysis by NMR of reaction
mixtures.
Nevertheless, enzyme dependent bromide elimination was observed using
the techniques of bromide ion electrode analysis.

These experiments

strongly indicated the mechanism of glyoxalase I proceeds through a fastshielded proton transfer with an enediol intermediate.

Of significance,

the elimination of the halide generating the quinoid-like structure XIX.
requires a disruption of the aromatic ring.

This loss of resonance energy

might be expected to constitute a formidable energy barrier to halide
release.

It appears that bromide ion is a sufficiently reactive leaving

group to over-come this energy barrier.
demonstrated no fluoride ion release.

Fluoride ion electrode studies

Therefore, it appears that fluoride

ion is not a sufficiently reactive leaving group to overcome the energy
barrier of disrupting the aromatic reasonance structure.

Consequently, if
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bromide ion elination could be successfully quantified, one might be able
to measure partitioning
fluoromethylglyoxal (96).

ratios as

Kozarich

&

Chari

did

with

The existence of various products is supported

by the tentative identification of the non-elimination product,

p-

bromomethylmandelic acid (XXIII) and the observation that bromide ion
release is an enzyme dependent process.

In the presence of glyoxalase I,

the trend appears to be toward total bromide elimination due to the
continuous re-entry of the thiohemiacetal and thioester product into the
active site for further processing.

While in the presence of glyoxalase I

and II, there appears to be a trend toward no further bromide release after
the final hydroxy-acid product is formed.
Hie demonstration of an enzyme dependent bromide ion release supports
the hypothesis that the quinoid-like intermediate, XIX. is formed at
active site.

This has important implications.

the

The quinoid-like

intermediate formed by bromide elimination takes on a planar configuration.
Thus,

it might be inferred that the active pocket is sufficiently

nonspecific to permit the formation of the planar quinoid-like
intermediate.

Of greater significance is that this compound is highly

susceptible to Michael addition by a nucleophile at the active site.

This

would then cause the covalent modification of the enzyme and thus
irreversibly inhibit it.

Such a possibility would represent the first

mechanism-based irreversible inhibitor of glyoxalase I.
Initial experiments studying the inhibition of glyoxalase I by
bromomethylphenylglyoxal provide strong evidence that the compound is
acting as a mechanism-based, irreversible inhibitor of glyoxalase I.

The

studies showed that the novel new haloketoaldehyde fulfills the initial
criteria (122) for identifying suicide inactivation.

The experiments

demonstrated the loss of enzyme activity was time dependent, following
first-order kinetics.

The rate of inactivation was found to be
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proportional to the inhibitor concentration.

Saturation kinetics are

observed at high concentrations of inhibitor (135).

Further experiments

that would allow us to definitively state that bromomethylphenylglyoxal is
an irreversible inhibitor include substrate protection studies, where the
rate of inactivation is decreased as one increases the concentration of
substrate (e.g. methylglyoxal).

Other important studies include extensive

dialysis and column separation to try and reactivate the enzyme.

For

further proof of the covalent modification of the enzyme, one could
radioactively label the inactivator and show that the radioactivity becomes
irreversibly associated with the protein.
Hie control experiments of the enzyme inhibition studies indicated an
alternative process by which enzyme inactivation could occur.

This was

demonstrated in experiments which contained bromomethylphenylglyoxal at
various concentrations incubated with glyoxalase I without GSH present.
This result suggests that a non-mechanism-based enzyme inactivation is
operative in the absence of GSH.
At low concentrations there was a slow inactivation of the enzyme
probably due to random alkylation of the enzyme by bromomethylphenylglyoxal
(See Fig. 13).

While at a

high concentration of

inhibitor,

this non-

FlGURE 13:

enzymatic inactivation appeared more rapid, the latter was later shown to
represent no more than 50% inactivation after 2 hrs. (135).

The above
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observations raise an interesting dilemma.

In the presence of GSH, which

"carries" the ketoaldehyde to the active site,

is the inactivation of the

enzyme due to an active site nucleophile simply displacing the bromide and
forming a covalent link (See Fig. 14)?

Or is the compound truly processed

Figure 14:

i

through the quinoid-like intermediate followed by Michael addition?

The

former mechanism, which is due to an intrinsically reactive

a -

halomethylene reacting with an active site nucleophile, would represent an
■affinity label" inactivation and not the hypothesized mechanism-based
inactivation.

In support of the former was our inability to identify

bromide elimination products which had not been covalently attached to the
protein.

However, there is also data that strongly supports the hypothesis

that bromomethylphenylglyoxal is being processed through the highly
reactive quinoid-like intermediate which then inactivates the enzyme.

If

enzymatic inactivation occurred by an active site nucleophile attacking the
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reactive

a -halomethylene, for every bromide ion released, one would

expect the result of an inactive enzyme.

Thus, for "affinity label"

inactivation, there would be a very small, almost nonmeasureable amount of
bromide ion released.

This was certainly not observed.

One observed a

significant amount of bromide ion release that was enzyme dependent.

On

the other hand, this finding is possible if the inhibitor proceeds through
the proposed quinoid-1 ike intermediate.

In such a scheme it is possible to

have bromide elimination without requiring enzyme inactivation.

Further

proof of the probability of mechanism-based enzyme inhibition over affinity
label type of inhibition is seen in the bromide ion electrode studies.

The

control experiment containing just inhibitor and glyoxalase I (no added
GSH) revealed that an immeasurably small amount of bromine was eliminated.
This observation indicates that the enzyme inactivation that was seen when
the inhibitor and glyoxalase I were incubated occurred by a very small
number of alkylations.

If it had occurred via numerous alkylations, than a

measureable quantity of bromide ion should have been present.

It also

gives strong evidence that bromomethylphenylglyoxal is being processed via
the proposed intermediate which allows for the observed enzyme dependent
bromide elimination.

This is the only explanation for the findings that

indicate that for inactivation to occur, bromide ion must be eliminated,
but bromide ion elimination does not necessarily need to cause enzymatic
inactivation.
Further proof is needed to definitively assign bromomethylphenyl¬
glyoxal as a mechanism based irreversible inactivator of glyoxalase I.
Besides the studies mentioned earlier which are required to conclude that a
compound is a suicide inhibitor, other useful studies could be designed.
One could prepare a compound like

BrCH2-C6H4-CH2CH0

undergo thiohemiacetal formation with GSH.

which would

The thiohemiacetal would be

able to specifically bind to the active site.

One could then compare the
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rate of enzymatic inactivation by this type of compound, which could only
cause enzyme inactivation by an "affinity label" type mechanism, versus
enzyme inactivation by bromomethylphenylglyoxal, which causes enzyme
inactivation via a mechanism-based process.

Such an experiment could give

further evidence toward solving the dilemma of mechanism-based inhibition
versus affinity label inhibition.
Hie studies of the halogenated methylphenylglyoxal's cytotoxic effect
on tumor cells in tissue culture and their anti-cancer activity in tumor¬
bearing mice strongly support the finding that p-bromomethylphenylglyoxal
is an inhibitor of glyoxalase I and can potentially act as a useful anti¬
neoplastic agent.

As expected, bromomethylphenylglyoxal inhibited the

growth of L1210 and P388 cell lines is tissue culture.

As an inhibitor of

glyoxalase I, the compound could cause the build-up of growth inhibiting
substances in cells in tissue culture and thus dramatically decrease tumor
cell growth.

When p-fluoromethylphenylglyoxal was incubated with the P388

and L1210 cell lines, some growth inhibition was noted.

The findings that

f 1 uoromethylphenylglyoxal inhibited tumor growth, while it was not an in
vitro mechanism-based irreversible inhibitor of yeast glyoxalase I, can be
explained by one of two mechanism.

Because fluoromethylphenlyglyoxal was

shown to be a substrate of glyoxalase I, it can act as a competitive
inhibitor.

As a competitive inhibitor, in vivo, it can cause an initial

accumulation of growth inhibiting substances that result in tumor growth
inhibition.

Another possible explanation of this compound's growth

inhibiting effect in vivo is that the mammalian glyoxalase I enzyme may
differ from the yeast enzyme and in contrast to the yeast enzyme the
mammalian enzyme may cause fluoride elimination and formation of the
reactive quinoid-1 ike intermediate that inactivates the enzyme.
In support of the discovery that bromo- and fluoromethylphenylglyoxal
cause tumor growth inhibition in tissue culture by specifically interacting
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with the glyoxalase enzyme system is the finding that their synthetic
precursors,

methylacetophenone,

p-fluoromethylacetophenone,

and p-

bromomethylacetophenone result in little to no inhibition of tumor growth
in tissue culture.
Brano- and fluororaethylphenylglyoxal were also tested in L1210 tumor¬
bearing mice by the intraperitoneal injection of the compounds for six
consecutive

days.

As

expected,

at

the

doses

tested,

fluoromethylphenylglyoxal showed no increased survival in the treated
tumor-bearing mice.

This is an agreement with the in vitro enzymatic

studies which demonstrated that the fluoro- compound did not act as an
irreversible inhibitor of glyoxalase I.

However, bromomethylphenylglyoxal

at 50 mg/kg and 25 mg/kg resulted in extreme toxicity.

The L1210 tumor¬

bearing mice only survived through one dose of the compound.

The mice

treated with this compound at 10 mg/kg and 5 mg/kg survived the complete
course of six treatments, but died before the non-treated controls.
lower doses, no significant increase in survival was noted.

At

The extreme

toxicity of bromomethylphenylglyoxal in tumor-bearing mice is in keeping
with the potent effect of an irreversible,
completely inactivates an enzyme.

suicide inhibitor which

In this case,

the inhibition of

glyoxalase I leads to the overwhelming accumulation of substances which
inhibit cell growth and division and cause the death of the animal.

Thus,

the treatment schedule of therapy beginning 24 hours after tumor
implantation followed by treatment for six consecutive days was not the
optimum regimen for evaluating the anti-cancer effects
bromomethylphenylglyoxal.

of p-

Perhaps a different evaluation program specified

by the Drug Evaluation Branch of the National Cancer Institute will yield
more definitive results.

One such evaluation involves the treatment of

tumor-bearing mice beginning 24 to 48 hours after tumor implantation
followed by treatment intervals of every fourth day (133).

Such an
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evaluation program could optimize the anti-tumor effect and diminish the
toxic effects of bromomethylphenylglyoxal.

.the cancer cell is unable to arrest growth
because it is unable to inactivate its glyoxalase, which destroys the ketone-aldehyde that
keeps the cell at rest...
-A. Szent-Gyorgyi (13)
The design and synthesis of inhibitors of specific key metabolic
enzymes has been an important new approach in the development of potential
anti-cancer agents. p-Bromomethylphenylglyoxal appears to be the first
mechanism-based, irreversible inhibitor of glyoxalase I.

This compound may

be a potential anti-neoplastic agent and may help to further elucidate the
definitive function of the glyoxalase enzyme system.

And if Szent-

Gydrgyi's theory is one day proven wrong, something will be left afterward.
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